Study guide
12.1 Malignant Hyperthermia: Presentation, Ryanodex/Dantrolene Protocol & ASC Preparedness
Certified Ambulatory Surgery Nurse CNAMB
Track your progress as you read
Finished sections get a check mark.
1 CNAMB Exam Blueprint, Eligibility & Test Strategy
Current CNAMB Exam Facts, Eligibility & Blueprint
2 Chapter 1: Preoperative Health Assessment & Diagnostic Evaluation
1.1 Patient Health History, Physical Assessment & Medication Reconciliation 1.2 Laboratory, Diagnostic & Cardiac Data Review in Ambulatory Surgery 1.3 Allergy Screening, Sensitivity Identification & Latex Precautions
3 Chapter 2: Risk Stratification, Anesthesia Screening & Pre-Op Clearance
2.1 ASA Physical Status Classification & ASC Patient Candidacy Criteria 2.2 Obstructive Sleep Apnea, Cardiovascular & Metabolic Risk Stratification
4 Chapter 3: Ambulatory Surgical Care Planning & Infection Prophylaxis
3.1 Perioperative Nursing Diagnoses & Individualized Ambulatory Care Plans 3.2 Surgical Site Infection (SSI) Prevention Bundles & Prophylactic Antibiotic Timing
5 Chapter 4: Patient Education, Vulnerable Populations & Discharge Prep
4.1 Preoperative Patient & Escort Education, Fasting Guidelines & NPO Rules 4.2 Health Literacy, Language Access & Cultural/Spiritual Care 4.3 Pediatric & Geriatric Ambulatory Care
6 Chapter 5: Surgical Asepsis, Sterile Technique & OR Environment
5.1 Principles of Surgical Asepsis, Sterile Field Integrity & Traffic Control 5.2 Surgical Hand Antisepsis, Gowning, Gloving & Draping Standards 5.3 Ambulatory OR Environmental Controls: HVAC, Temperature, Humidity & Air Exchanges
7 Chapter 6: Patient Positioning, Equipment Safety & Intraoperative Monitoring
6.1 Surgical Positioning: Alignment, Pressure Injury Prevention & Nerve Protection 6.2 Safe Use of Electrosurgery Units (ESU), Surgical Lasers & Smoke Evacuation 6.3 Intraoperative Patient Monitoring & Anesthesia Assist (MAC, General, Regional) 6.4 Surgical Counts, Specimen Management Protocols & Wound Classification 6.5 Intraoperative Medication, Solution & Fluid Safety 6.6 Implants, Explants, Radiation & Hazardous Materials
8 Chapter 7: Interdisciplinary Communication & Handoff Protocols
7.1 Structured Handoff Protocols: SBAR, IPASS & Care Transitions in the ASC 7.2 Universal Protocol, Time-Out Verification & Wrong-Site Surgery Prevention
9 Chapter 8: Clinical Documentation, Electronic Health Records & Informed Consent
8.1 Ambulatory Nursing Documentation Standards, Timelines & Legal Integrity 8.2 Informed Consent Verification, Patient Autonomy & Refusal of Care
10 Chapter 9: Phase I Postanesthesia Care & Complication Management
9.1 Phase I PACU Airway Management, Oxygenation & Hemodynamic Stabilization 9.2 Postoperative Pain Management & PONV Multimodal Protocols in the ASC 9.3 Emergent Postoperative Complications: Laryngospasm, Hemorrhage & Hypothermia
11 Chapter 10: Phase II Recovery, Discharge Criteria & Post-Discharge Safety
10.1 Aldrete Scoring, PADSS (Post-Anesthesia Discharge Scoring System) & Discharge Readiness 10.2 Patient & Escort Discharge Instructions, Home Care & Follow-Up
12 Chapter 11: Instrument Processing, Sterilization & Supply Management
11.1 Point-of-Use Treatment, Decontamination & Cleaning of Surgical Instruments 11.2 High-Level Disinfection, Steam Sterilization & Low-Temperature Methods 11.3 Sterilization Process Monitoring: Chemical/Biological Indicators & Sterile Storage
13 Chapter 12: Ambulatory Perioperative Emergencies
12.1 Malignant Hyperthermia: Presentation, Ryanodex/Dantrolene Protocol & ASC Preparedness 12.2 Local Anesthetic Systemic Toxicity (LAST): Recognition, Lipid Emulsion & Resuscitation 12.3 Surgical Suite Fires, Code Blue & Emergency Transfer/Evacuation in the ASC 12.4 Anaphylaxis, Hemorrhage, Age-Specific Arrest & Disaster Response
14 Chapter 13: Management of Personnel, Services, and Materials
13.1 ASC Staffing Models, Competency Verification & Rapid Turnover Coordination 13.2 Inventory Management, Surgeon Preference Cards & Cost-Containment Strategies 13.3 Medical Device Safety, Preventive Maintenance & Vendor Management 13.4 Product Evaluation, Recalls, PPE & Environmental Stewardship
15 Chapter 14: Legal Standards, Regulatory Framework & Professional Ethics
14.1 Nursing Scope of Practice, UAP Delegation & ANA/AORN Professional Standards 14.2 Ethics in Ambulatory Care: Patient Advocacy, Confidentiality (HIPAA) & Mandatory Reporting 14.3 Competence, Bias, Civility & Evidence-Based Practice
16 Chapter 15: Quality Improvement, Accreditation & Evidence-Based Practice
15.1 ASC Accreditation Standards: AAAHC, The Joint Commission & CMS Conditions for Coverage 15.2 Quality Improvement, Infection Surveillance (NHSN), Incident Reporting & Root Cause Analysis 15.3 Certification Value, Professional Growth & Lifelong Learning (CCI CNAMB Maintenance)
12.1 Malignant Hyperthermia: Presentation, Ryanodex/Dantrolene Protocol & ASC Preparedness
Key Takeaways Explain This Topic AI
Malignant Hyperthermia (MH) is an autosomal dominant pharmacogenetic disorder of skeletal muscle sarcoplasmic reticulum (RYR1 and CACNA1S mutations) triggered by volatile halogenated anesthetics and succinylcholine.
The earliest and most sensitive indicators of an MH crisis are unexplained sinus tachycardia and an abrupt, severe elevation in end-tidal CO2 (EtCO2 doubling or tripling) that is refractory to aggressive hyperventilation.
Hyperthermia is a late sign of MH that can escalate by 1°C to 2°C every 5 minutes (exceeding 42°C / 108°F), underscoring that treatment must begin immediately upon hypercarbia and rigidity without waiting for a temperature spike.
Ryanodex (nanocrystalline dantrolene) provides 250 mg per vial reconstituted in 5 mL sterile water in under 1 minute (initial dose 2.5 mg/kg IV), revolutionizing rapid delivery compared to generic dantrolene which requires 36 vials reconstituted with 60 mL water each.
MHAUS and accreditation standards mandate that any ASC administering triggering agents stock a minimum of 36 vials of generic dantrolene (or 3 vials of Ryanodex), maintain active cooling capabilities, and conduct interdisciplinary MH mock drills at least annually.
Last updated: September 2026
Malignant Hyperthermia: Presentation, Ryanodex/Dantrolene Protocol & ASC Preparedness
Core Principle: Malignant Hyperthermia (MH) is a fulminant, pharmacogenetic hypermetabolic crisis of skeletal muscle triggered by volatile halogenated anesthetics or succinylcholine. In freestanding ambulatory surgery centers (ASCs), where specialized code teams and critical care units do not exist on-site, the perioperative nurse's ability to instantly recognize early non-thermal warning signs and execute the MHAUS emergency treatment protocol within minutes is the definitive factor separating patient survival from fatal cardiovascular collapse.
Pathophysiology & Genetics of Malignant Hyperthermia
Malignant Hyperthermia is inherited as an autosomal dominant trait with variable penetrance and expressivity. Approximately 70% to 80% of susceptible individuals harbor mutations in the RYR1 gene (ryanodine receptor type 1), located on chromosome 19q13.1, which encodes the principal calcium-release channel in the skeletal muscle sarcoplasmic reticulum (SR). A smaller subset of individuals possesses mutations in the CACNA1S gene , encoding the alpha-1S subunit of the voltage-dependent L-type calcium channel (dihydropyridine receptor) on the transverse tubule (T-tubule).
The Hypermetabolic Cascade
Uncontrolled Sarcoplasmic Calcium Influx: Upon exposure to a triggering agent, defective ryanodine channels lock open, causing an uncontrolled, massive efflux of stored calcium (Ca²⁺) from the sarcoplasmic reticulum into the skeletal muscle myoplasm.
Sustained Actin-Myosin Cross-Bridging: Intracellular calcium saturation prevents troponin from inhibiting tropomyosin, locking actin and myosin into relentless, uninhibited cross-bridging and muscle contraction.
ATP Depletion & Hypermetabolism: Muscle cells desperately attempt to sequester excess calcium back into the SR via calcium ATPase pumps and restore cellular homeostasis. This consumes massive quantities of adenosine triphosphate (ATP), stimulating aerobic and anaerobic glycolysis, cellular oxygen consumption (VO₂), and carbon dioxide production (VCO₂) by two to five times baseline levels .
Rhabdomyolysis & Sarcolemmal Rupture: Cellular energy starvation leads to hyperthermia (heat produced as a byproduct of uncontrolled ATP breakdown), severe lactic and respiratory acidosis, and failure of cellular membrane integrity. Muscle fibers rupture (rhabdomyolysis), releasing toxic intracellular contents— potassium (K⁺), creatine kinase (CK), and myoglobin —into systemic circulation.
Triggering vs. Safe Non-Triggering Anesthetic Agents
The ambulatory perioperative team must distinguish between known triggering pharmacological agents and safe alternatives for known MH-susceptible (MHS) patients or family members.
Category Pharmacological Agents Clinical Action & Guidance
Triggering Volatile Halogenated Inhalation Anesthetics • Sevoflurane (Ultane); • Desflurane (Suprane); • Isoflurane (Forane); • Halothane, Enflurane (historical) Strictly contraindicated in MH-susceptible individuals. Triggers calcium release channel opening. Never introduce to an MHS patient.
Triggering Depolarizing Neuromuscular Blocker • Succinylcholine (Anectine, Quelicin) Strictly contraindicated. Causes prolonged depolarization, triggering massive SR calcium dump and masseter spasm.
Safe Intravenous Anesthetics & Induction Agents • Propofol (Diprivan); • Etomidate (Amidate); • Ketamine (Ketalar); • Barbiturates (Methohexital); • Dexmedetomidine (Precedex) Completely safe. Total Intravenous Anesthesia (TIVA) with propofol is the gold standard for general anesthesia in MHS patients.
Safe Non-Depolarizing Neuromuscular Blockers • Rocuronium (Zemuron); • Vecuronium (Norcuron); • Cisatracurium (Nimbex) Completely safe. Act competitively on nicotinic acetylcholine receptors without opening intracellular SR calcium channels.
Safe Reversal Agents • Sugammadex (Bridion); • Neostigmine / Glycopyrrolate Completely safe for non-depolarizing paralytic reversal.
Safe Opioids & Inhaled Gases • Fentanyl , Sufentanil, Remifentanil, Hydromorphone, Morphine; • Nitrous Oxide (N₂O); • Medical Air and 100% Oxygen Completely safe. Nitrous oxide is not a halogenated gas and does not trigger MH.
Safe Local & Regional Anesthetics • Amides: Lidocaine, Bupivacaine, Ropivacaine, Mepivacaine; • Esters: Procaine, Chloroprocaine, Tetracaine Completely safe. Historical myths regarding amide local anesthetics triggering MH have been thoroughly refuted by MHAUS.
Clinical Presentation & Timeline of Symptoms
Malignant Hyperthermia is insidious and dynamic. It can manifest immediately upon induction, intraoperatively during maintenance, or up to several hours postoperatively in the Phase I PACU. Recognition depends on understanding the chronological sequence of physiological decompensation. ┌────────────────────────────────────────────────────────────────────────┐
- │ CHRONOLOGICAL SPECTRUM OF MH MANIFESTATIONS │
- ├────────────────────────────────────────────────────────────────────────┤
- │ [EARLIEST] ↳ Hypercarbia (EtCO2 doubling/tripling, refractory) │
- │ ↳ Unexplained sinus tachycardia & tachypnea │
- │ [EARLY] ↳ Masseter Muscle Rigidity (MMR / "jaws of steel") │
- │ ↳ Generalized skeletal muscle rigidity │
- │ ↳ Skin mottling, cyanosis, and profuse diaphoresis │
- │ [DEVELOPING]↳ Mixed metabolic and respiratory acidosis (pH <7.15) │
- │ ↳ Hyperkalemia (peaked T waves, ventricular ectopy) │
- │ [LATE] ↳ Hyperthermia (>38.8°C / 101.8°F up to >42°C / 108°F) │
- │ ↳ Gross rhabdomyolysis: Cola-colored urine (myoglobinuria) │
- │ ↳ Massive CK elevation (>20,000 - 100,000+ IU/L) │
- │ ↳ Disseminated Intravascular Coagulation (DIC) │
- └────────────────────────────────────────────────────────────────────────┘
- 1. Earliest and Most Sensitive Signs
Hypercarbia (Rapid, Disproportionate Rise in EtCO₂): The earliest, most reliable objective indicator of MH. The end-tidal carbon dioxide abruptly doubles or triples (rising rapidly to 60, 80, 100+ mmHg) despite aggressive attempts by the anesthesia provider to hyperventilate the patient (e.g., doubling minute ventilation from 6 L/min to 12 L/min). Soda lime absorbent cannisters turn purple almost instantly and become intensely hot to the touch due to extreme exothermic CO₂ absorption.
Unexplained Sinus Tachycardia: Heart rate jumps significantly above baseline without surgical stimulation, light anesthesia, or hypovolemia.
Tachypnea: In spontaneously breathing or sedated patients, rapid, labored breathing occurs in response to metabolic drive.
2. Muscle Rigidity & Masseter Spasm
Masseter Muscle Rigidity (MMR / Trismus): Following succinylcholine administration during induction, jaw muscles clench tight ("jaws of steel"), rendering direct laryngoscopy and mouth opening physically impossible. While isolated mild jaw stiffness can occur with succinylcholine, intractable rigidity that prevents airway instrumentation is considered an MH crisis until proven otherwise in approximately 50% of cases .
Generalized Muscle Rigidity: Skeletal muscles throughout the body become board-like, stiff, and unyielding, persisting despite administration of non-depolarizing paralytics (such as rocuronium).
3. Progressive Acidosis & Hyperkalemia
Severe Mixed Acidosis: Arterial blood gas (ABG) analysis reveals profound metabolic lactic acidosis accompanied by respiratory acidosis (pH <7.10–7.20, base excess worse than -10 mEq/L, PaCO₂ >60–90 mmHg). Arterial and venous oxygen saturation drops dramatically as tissues rapidly consume oxygen.
Hyperkalemia: Massive potassium release from damaged sarcolemma drives serum potassium to life-threatening levels (K⁺ >6.0–8.0 mEq/L). The electrocardiogram (ECG) shows tall, peaked T waves, widening QRS complexes, ventricular bigeminy, ventricular tachycardia, and cardiac arrest.
4. Late Signs: Hyperthermia & Rhabdomyolysis
Hyperthermia is a LATE Sign: Core body temperature does not rise initially! When it does rise, it escalates catastrophically by 1°C to 2°C every 5 minutes , rapidly reaching 40°C to 42°C+ (104°F to 108°F+) . Clinical Rule: Never wait for a temperature elevation to diagnose or treat Malignant Hyperthermia! Waiting for fever results in severe neurological injury and mortality.
Rhabdomyolysis & Myoglobinuria: Myoglobin released into circulation filters through the glomeruli, turning urine dark brown, tea-colored, or "cola-colored." Serum creatine kinase (CK) peaks 12 to 24 hours post-crisis, often exceeding 20,000 to 100,000+ IU/L. Precipitation of myoglobin casts in renal tubules precipitates acute tubular necrosis and acute renal failure.
The MHAUS Emergency Treatment Protocol
The Malignant Hyperthermia Association of the United States ( MHAUS ) establishes a strict, time-critical sequence of life-saving interventions. The perioperative team must execute these actions simultaneously.
Step 1: Discontinue Triggers, Call for Help & Bring MH Cart
Immediately stop volatile anesthetics and succinylcholine. Notify the surgeon to halt the surgical procedure immediately, close or pack wounds, and prepare for emergent stabilization.
Call for help and sound the facility emergency alarm. Mobilize all available nurses, technicians, and anesthesia personnel. Bring the dedicated MH Emergency Cart directly into the operating room.
Step 2: Hyperventilate with 100% Oxygen & Apply Charcoal Filters
Turn anesthetic vaporizers completely OFF .
Hyperventilate the patient with 100% oxygen at maximum fresh gas flows (≥10 L/min) to blow off excess CO₂ and meet soaring cellular oxygen demands.
Do NOT waste time changing the anesthesia circuit or machine! Immediately attach activated charcoal filters (Vapor-Clean) to both the inspiratory and expiratory limbs of the breathing circuit. These filters scrub trace volatile gases from the circuit within 60 to 90 seconds, maintaining volatile concentrations below 5 ppm.
Step 3: Administer Dantrolene Sodium Immediately
Dantrolene sodium is a hydantoin derivative that binds specifically to the RYR1 ryanodine receptor , inhibiting calcium release from the sarcoplasmic reticulum into the myoplasm. It uncouples the hypermetabolic crisis without affecting cardiac or smooth muscle contractility.
Comparison: Ryanodex vs. Generic Dantrolene (Dantrium / Revonto)
Clinical Characteristic Ryanodex (Nanocrystalline Dantrolene) Generic Dantrolene (Dantrium / Revonto)
Drug Formulation Nanocrystalline suspension with mannitol & polysorbate 80 Lyophilized powder requiring extensive dissolution
Concentration per Vial 250 mg per vial 20 mg per vial
Diluent & Reconstitution Volume 5 mL sterile water (preservative-free) per vial 60 mL sterile water (preservative-free) per vial
Reconstitution Speed Dissolves in <1 minute with gentle shaking Requires several minutes of vigorous shaking per vial
- Vials for 70 kg Patient (2.5 mg/kg) 1 vial (250 mg provides initial 175 mg dose) 9 vials (180 mg total)
- Total Diluent Volume Needed 5 mL sterile water 540 mL sterile water
- Minimum Stocking Mandate in ASC 3 vials (750 mg total) 36 vials (720 mg total) + 36 vials sterile water
Personnel Required to Reconstitute 1 nurse can reconstitute and push in 60 seconds 3 to 4 staff members required to reconstitute 36 vials
Initial Dosing: Administer dantrolene 2.5 mg/kg IV push rapidly via large-bore intravenous access.
Repeat Dosing: Repeat boluses of 1 to 2.5 mg/kg IV every 5 to 10 minutes until clinical signs abate (EtCO2 normalizes, tachycardia resolves, muscle rigidity softens, and temperature stabilizes).
Maximum Dose: The standard initial ceiling is 10 mg/kg , but doses exceeding 20 mg/kg may be necessary in fulminant cases. If no response is observed after 10 mg/kg, alternative diagnoses (e.g., thyroid storm, sepsis, pheochromocytoma) must be urgently reconsidered.
Step 4: Treat Life-Threatening Hyperkalemia
Hyperkalemia (K⁺ >6.0 mEq/L) drives fatal ventricular arrhythmias and must be managed aggressively:
Membrane Stabilization: Administer Calcium Chloride 10% (10 mg/kg IV, up to 1,000 mg) or Calcium Gluconate 10% (30 mg/kg IV, up to 3,000 mg) to antagonize cardiac membrane excitability.
Intracellular Shift: Administer Regular Insulin 10 units IV combined with 50% Dextrose (D50W) 50 mL (25 grams) to drive potassium into cells. Check blood glucose every 15 minutes.
Alkalinization: Administer Sodium Bicarbonate (1–2 mEq/kg IV) to shift potassium intracellularly and buffer profound metabolic acidosis.
CRITICAL WARNING: Never administer Calcium Channel Blockers (e.g., Verapamil, Diltiazem) in Malignant Hyperthermia! The combination of dantrolene and calcium channel blockers causes catastrophic, refractory hyperkalemia and lethal myocardial depression.
Step 5: Active Patient Cooling Protocol
Active cooling must commence as soon as dantrolene is pushed, utilizing all available modalities:
Infuse chilled normal saline (0.9% NaCl chilled to 4°C) intravenously at 1,000 mL every 30 minutes (up to 2,000 to 3,000 mL).
Apply ice packs to areas of high vascularity: axillae, groin, lateral neck, and head .
Perform cold saline body cavities lavage: nasogastric tube gastric lavage and urinary bladder irrigation via a three-way Foley catheter.
CEASE COOLING THRESHOLD: Stop all active cooling measures when core body temperature reaches 38.0°C (100.4°F) ! Continuing cooling below 38.0°C precipitates profound rebound hypothermia, shivering (which skyrockets oxygen demand), and coagulopathy.
Step 6: Maintain Renal Perfusion & Diuresis
To prevent acute tubular necrosis from myoglobinuria, insert an indwelling urinary catheter with an integrated temperature sensor:
Target and maintain a robust urine output of >1 to 2 mL/kg/hr .
Administer intravenous crystalloids, Mannitol (0.25 g/kg IV; note: Ryanodex contains 0.163 g mannitol per vial), and Furosemide (0.5 to 1.0 mg/kg IV) to flush myoglobin casts through renal tubules.
Alkalinize the urine by maintaining systemic pH >7.20 with sodium bicarbonate, as alkaline urine prevents myoglobin crystallization in distal nephrons.
Step 7: Call the MHAUS 24-Hour Hotline
As soon as initial interventions are underway, designate a nurse to call the MHAUS Emergency Hotline: 1-800-644-9737 (1-800-MH-HYPER) . An experienced, on-call anesthesiologist specializing in Malignant Hyperthermia will provide real-time, step-by-step clinical guidance, medication titration, and transfer consultation.
Step 8: Emergency Transfer to Inpatient Critical Care (ICU)
Freestanding ambulatory surgery centers cannot manage post-MH recovery. Once the patient is stabilized:
Activate EMS 911 for emergent ALS transfer to an acute care hospital intensive care unit.
Recrudescence Warning: Malignant Hyperthermia recurs ( recrudescence ) in 20% to 25% of cases within 24 to 36 hours of the primary event. Patients require continuous ICU invasive arterial pressure, core temperature, blood gas, and electrolyte monitoring, receiving maintenance dantrolene at 1 mg/kg IV every 4 to 6 hours for at least 24 hours , with further dosing and monitoring guided by MHAUS criteria and the patient’s course.